1. Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC
   Jacqueline V. Aredo et al, 2021, Journal of Thoracic Oncology CrossRef
2. Improved survival in patients with unresectable stage III EGFR‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
   Sheng‐Yuan Wang et al, 2022, Thoracic Cancer CrossRef
3. Comparison of treatment regimens for unresectable stage III epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer
   Xin Dai et al, 2024, Chinese Medical Journal CrossRef
4. Comparative effectiveness of concurrent chemoradiotherapy versus EGFR‐tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR
   Te‐Chun Hsia et al, 2018, Thoracic Cancer CrossRef
5. Pattern of failure and clinical value of local therapy for oligo‐recurrence in locally advanced non‐small cell lung cancer after definitive chemoradiation: Impact of driver mutation status
   Jinmeng Zhang et al, 2023, Cancer Medicine CrossRef
6. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
   Terufumi Kato et al, 2024, Lung Cancer CrossRef
7. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
   Jacqueline V. Aredo et al, 2021, Journal of Thoracic Oncology CrossRef
8. Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study (HOT2101)
   Kosuke Tsuji et al, 2024, Cancer Science CrossRef
9. The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis
   Qin Qin et al, 2019, Expert Review of Anticancer Therapy CrossRef
10. Induction EGFR tyrosine kinase inhibitors prior to definitive chemoradiotherapy in unresectable stage III EGFR-mutated non-small cell lung cancer
    Jacqueline V. Aredo et al, 2022, Cancer Treatment and Research Communications CrossRef
11. Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
    S. Lu et al, 2024, Annals of Oncology CrossRef
12. Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
    Yang Liu et al, 2023, Aging CrossRef
13. An Observational Study on Treatment Outcomes in Patients With Stage III NSCLC in Taiwan: The KINDLE Study
    Po-Lan Su et al, 2022, JTO Clinical and Research Reports CrossRef
14. Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer
    Huan-Wei Liang et al, 2024, Aging CrossRef
15. Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer
    Jerold Loh et al, 2023, Expert Review of Anticancer Therapy CrossRef